AIMS: The association of QRS duration (QRSd) with morbidity and mortality is understudied in patients with atrial fibrillation (AF). We sought to assess any association of prolonged QRS with increased risk of death or hospitalization among patients with AF. METHODS AND RESULTS:QRS duration was retrieved from the baseline electrocardiograms of patients enroled in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study and divided into three categories: <90, 90-119, ≥120 ms. Cox models were applied relating the hazards of mortality and hospitalizations to QRSd. Among 3804 patients with AF, 593 died and 2305 were hospitalized. Compared with those with QRS < 90 ms, patients with QRS ≥ 120 ms, had an increased mortality [hazard ratio (HR) 1.61, 95% confidence interval (CI): 1.29-2.03, P < 0.001] and hospitalizations (HR 1.14, 95% CI: 1.07-1.34, P = 0.043) over an average follow-up of 3.5 years. Importantly, for patients with QRS 90-119 ms, mortality and hospitalization were also increased (HR 1.31, P = 0.005 and 1.11, P = 0.026, respectively). In subgroup analysis based on heart failure (HF) status (previously documented or ejection fraction <40%), mortality was increased for QRS ≥ 120 ms patients with (HR 1.87, P < 0.001) and without HF (HR 1.63, P = 0.02). In the QRS 90-119 ms group, mortality was increased (HR 1.38, P = 0.03) for those with HF, but not significantly among those without HF (HR 1.23, P = 0.14). CONCLUSION: Among patients with AF, QRSd ≥ 120 ms was associated with a substantially increased risk for mortality (all-cause, cardiovascular, and arrhythmic) and hospitalization. Interestingly, an increased mortality was also observed among those with QRS 90-119 ms and concomitant HF. Published on behalf of the European Society of Cardiology. All rights reserved.
RCT Entities:
AIMS: The association of QRS duration (QRSd) with morbidity and mortality is understudied in patients with atrial fibrillation (AF). We sought to assess any association of prolonged QRS with increased risk of death or hospitalization among patients with AF. METHODS AND RESULTS: QRS duration was retrieved from the baseline electrocardiograms of patients enroled in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) study and divided into three categories: <90, 90-119, ≥120 ms. Cox models were applied relating the hazards of mortality and hospitalizations to QRSd. Among 3804 patients with AF, 593 died and 2305 were hospitalized. Compared with those with QRS < 90 ms, patients with QRS ≥ 120 ms, had an increased mortality [hazard ratio (HR) 1.61, 95% confidence interval (CI): 1.29-2.03, P < 0.001] and hospitalizations (HR 1.14, 95% CI: 1.07-1.34, P = 0.043) over an average follow-up of 3.5 years. Importantly, for patients with QRS 90-119 ms, mortality and hospitalization were also increased (HR 1.31, P = 0.005 and 1.11, P = 0.026, respectively). In subgroup analysis based on heart failure (HF) status (previously documented or ejection fraction <40%), mortality was increased for QRS ≥ 120 ms patients with (HR 1.87, P < 0.001) and without HF (HR 1.63, P = 0.02). In the QRS 90-119 ms group, mortality was increased (HR 1.38, P = 0.03) for those with HF, but not significantly among those without HF (HR 1.23, P = 0.14). CONCLUSION: Among patients with AF, QRSd ≥ 120 ms was associated with a substantially increased risk for mortality (all-cause, cardiovascular, and arrhythmic) and hospitalization. Interestingly, an increased mortality was also observed among those with QRS 90-119 ms and concomitant HF. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: D G Wyse; A L Waldo; J P DiMarco; M J Domanski; Y Rosenberg; E B Schron; J C Kellen; H L Greene; M C Mickel; J E Dalquist; S D Corley Journal: N Engl J Med Date: 2002-12-05 Impact factor: 91.245
Authors: Michael R Bristow; Leslie A Saxon; John Boehmer; Steven Krueger; David A Kass; Teresa De Marco; Peter Carson; Lorenzo DiCarlo; David DeMets; Bill G White; Dale W DeVries; Arthur M Feldman Journal: N Engl J Med Date: 2004-05-20 Impact factor: 91.245
Authors: Sudhir Kurl; Timo H Mäkikallio; Pentti Rautaharju; Vesa Kiviniemi; Jari A Laukkanen Journal: Circulation Date: 2012-05-21 Impact factor: 29.690
Authors: Mark S Turner; Rob A Bleasdale; Dragos Vinereanu; Catherine E Mumford; Vince Paul; Alan G Fraser; Michael P Frenneaux Journal: Circulation Date: 2004-05-17 Impact factor: 29.690
Authors: S Baldasseroni; L De Biase; C Fresco; N Marchionni; M Marini; G Masotti; G Orsini; M Porcu; F Pozzar; M Scherillo; A P Maggioni Journal: Eur Heart J Date: 2002-11 Impact factor: 29.983
Authors: Lasse Oikarinen; Markku S Nieminen; Matti Viitasalo; Lauri Toivonen; Sverker Jern; Björn Dahlöf; Richard B Devereux; Peter M Okin Journal: Hypertension Date: 2004-03-22 Impact factor: 10.190
Authors: Joseph N Gigliotti; Mandeep S Sidhu; Alina M Robert; Jonathan S Zipursky; Jeremiah R Brown; Salvatore P Costa; Robert T Palac; David A Steckman; David J Malenka; Alan T Kono; Mark L Greenberg Journal: Clin Cardiol Date: 2017-06-06 Impact factor: 2.882
Authors: Stefanie Aeschbacher; Wesley T O'Neal; Philipp Krisai; Laura Loehr; Lin Y Chen; Alvaro Alonso; Elsayed Z Soliman; David Conen Journal: Int J Cardiol Date: 2018-09-01 Impact factor: 4.164
Authors: Chunlian Zhong; He Chang; Yang Wu; Li Zhou; Yan Wang; Mingyan Wang; Peng Wu; Zhi Qi; Jun Zou Journal: J Cell Mol Med Date: 2018-04-17 Impact factor: 5.310
Authors: Daniel Antwi-Amoabeng; Sunil Sathappan; Bryce D Beutler; Mark B Ulanja; Munadel Awad; Nageshwara Gullapalli; Phillip Duncan; T David Gbadebo Journal: Clin Pract Date: 2022-07-15